MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
New Jersey
*Industry: New Jersey
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)*
Organization & Developments: Tonix
Parents
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)*
Children
*Developing prescription therapeutics for chronic Central Nervous System (CNS) conditions, such as Fibromyalgia Syndrome and Post-Traumatic Stress Disorder.
*Focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project
2018: Tonix's Fast Track Designation Is A Win, But New PTSD Data Is Coming Soon_seekingalpha.com
2019: Tonix loses Army USAMMDA R&D contract, gains chance to retain FDA breakthrough status
2021: Small, struggling biotech winds up with a 3X loser as another PhIII of its lead drug collapses
2021: Tonix Pharma: Interesting Molecule In Fibromyalgia, But Generic Availability Is A Concern
2021: Tonix Pharmaceuticals: Still Toxic Until Proven Otherwise
2022: Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
2025: Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)
2025: Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet
2025: Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?
2025: Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity
Jumps
*Key People: Tonix
Finance & Acquisitions: Tonix